When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
CAPR - Capricor Therapeutics to review CAP-1002 data with FDA
Capricor Therapeutics Inc.
Capricor Therapeutics (NASDAQ:CAPR) has been granted a Type B End-of-Phase 2 meeting with the FDA to discuss the prespecified interim analysis of its HOPE 2 trial that evaluated CAP-1002 in steroid-treated boys and young men with Duchenne muscular dystrophy (DMD).
More news on: Capricor Therapeutics, Inc., Healthcare stocks news,